Patents Assigned to Octoplus B.V.
  • Patent number: 6395302
    Abstract: The invention relates to a method for the preparation of microencapsulated colloidal systems such as liposomes, i.e., microspheres which comprise colloidal systems. These microencapsulated colloidal systems can be used as controlled release systems for the delivery of active ingredients in in vivo and in vitro applications. A method is provided in which the colloidal systems are added to a phase which comprises a water soluble crosslinkable polymer followed by formation of microspheres.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: May 28, 2002
    Assignee: Octoplus B.V.
    Inventors: Wilhelmus Everhardus Hennink, Okke Franssen
  • Patent number: 6303148
    Abstract: A process for the preparation of a controlled release system, comprising forming of an aqueous two-phase system form at least two water soluble polymers which are incompatible in solution, at least one of these polymers being cross-linkable, the cross-linkable polymer phase being emulsified in the other polymer phase; adding at least one relesable compound which is soluble in the cross-linked polymer phase in the aqueous solution, allowing the releasable compound to diffuse in the cross linkable polymer phase; cross-linking the cross-linkable polymer before or after the releasable compound is added, preferably to a degree that the pores in the cross-liked structure are substantially smaller than the particle size of the releasable compound; and separating the cross-linked structures enclosing the release able compound from the other phase. Further, the invention relates to microspheres, at least 80 wt.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: October 16, 2001
    Assignee: Octoplus B.V.
    Inventors: Wilhelmus Everhardus Hennink, Okke Franssen
  • Patent number: 6303300
    Abstract: Water soluble polymers or polymeric hydrogels are used to encapsulate antigen to form vaccines. The antigen is mixed with a polymer solution, microparticles are formed of the polymer and antigen, and, optionally, the polymer is crosslinked to form a stable microparticle. Preferred polymers are alginate and polyphospazenes, and mixtures thereof. Microparticles can be administered parenterally or mucosally. For oral delivery, the microparticles are preferably fifteen microns or less in diameter, and adhere to the mucosal lining of the gastointestinal tract, increasing uptake by the reticuloendothelium.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: October 16, 2001
    Assignees: Introgen B.V., Octoplus B.V., Universiteit Utrecht
    Inventors: Wilhelmus Everhardus Hennink, Abraham Bout
  • Patent number: 5985573
    Abstract: The present invention relates to a synthetic transfection or blocking system comprising as a carrier a cationic, water soluble or water dispersable polyacrylate, a polyacrylamide, a poly(C.sub.1-6 alkyl)acrylate or poly(C.sub.1-6 alkyl)acrylamide. In addition, it relates to a method for introducing DNA fragments in target cells, comprising contacting these DNA fragments with a polyacrylate, a polyacrylamide, a poly(C.sub.1-6 alkyl)acrylate or poly(C.sub.1-6 alkyl)acrylamide, which is at least partially substituted with cationic substituents and subsequently contacting the obtained transfection system with target cells. Finally, the invention involves the use of a polyacrylate, a polyacrylamide, a poly(C.sub.1-6 alkyl)acrylate or poly(C.sub.1-6 alkyl)acrylamide, which is at least partially substituted with cationic substituents as a DNA carrier system.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: November 16, 1999
    Assignee: Octoplus, B.V.
    Inventors: Wilhelmus Everhardus Hennink, Petra van de Wetering
  • Patent number: 5914231
    Abstract: The present invention to a synthetic transfection system comprising as a carrier a cationic, water dispersible polyphosphazene. In addition, it relates to a method for introducing DNA fragments in target cells, comprising contacting these DNA fragments with a polyphosphazene which is at least partially substituted with cationic substituents and subsequently contacting the obtained transfection system with target cells. Finally, the invention involves the use of a polyphosphazene which is at least partially substituted with cationic substituents as a transfection vehicle.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: June 22, 1999
    Assignees: Universiteit Utrecht Introgene B.V., Octoplus B.V.
    Inventors: Wilhelmus Everhardus Hennink, Abraham Bout